Newron Pharmaceuticals S.p.A. (NWPHF)

Newron Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 15, 2024	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	507	192	105	30	32	43
Market Cap Growth	149.78%	83.21%	250.69%	-5.67%	-26.87%	-62.94%
Enterprise Value	518	231	140	47	38	27
Last Close Price	9.36	9.36	5.22	2.10	2.10	2.44
PE Ratio	17.04	11.72	-	-	-	-
PS Ratio	7.21	3.61	10.48	4.59	4.84	6.74
PB Ratio	272.86	127.32	-3.17	-1.99	8.98	2.06
P/TBV Ratio	273.04	127.32	-	-	8.98	2.06
EV/Sales Ratio	7.13	4.34	13.95	7.26	5.77	4.13
EV/EBITDA Ratio	12.06	8.52	-	-	-	-
EV/EBIT Ratio	12.13	8.53	-	-	-	-
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-
Net Debt / Equity Ratio	5.92	27.88	-1.20	-1.63	2.73	-0.28
Net Debt / EBITDA Ratio	0.27	1.55	-3.12	-1.72	-0.69	0.27
Net Debt / FCF Ratio	0.38	-2.31	-3.53	-2.06	-0.74	0.31
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%
Return on Invested Capital (ROIC)	263.58%	80.74%	-157.51%	-130.08%	-103.26%	-134.50%
Return on Capital Employed (ROCE)	165.20%	64.80%	380.00%	-41.40%	-26.40%	-40.80%
Earnings Yield	5.87%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%
FCF Yield	5.68%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.